Cart
sales@molnova.com
Goxalapladib
CAS No. 412950-27-7
Goxalapladib( —— )
Catalog No. M35993 CAS No. 412950-27-7
Goxalapladib（GSK 677116） is a small molecule compound that can be used to treat cardiovascular risks associated with atherosclerosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 276 | In Stock |
|
| 10MG | 394 | In Stock |
|
| 25MG | 616 | In Stock |
|
| 50MG | 830 | In Stock |
|
| 100MG | 1097 | In Stock |
|
| 200MG | 1507 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGoxalapladib
-
NoteResearch use only, not for human use.
-
Brief DescriptionGoxalapladib（GSK 677116） is a small molecule compound that can be used to treat cardiovascular risks associated with atherosclerosis.
-
DescriptionGoxalapladib（GSK 677116） is a small molecule compound that can be used to treat cardiovascular risks associated with atherosclerosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number412950-27-7
-
Formula Weight718.75
-
Molecular FormulaC40H39F5N4O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C(N(CC1=CC=C(C=C1)C2=CC=C(C(F)(F)F)C=C2)C3CCN(CCOC)CC3)=O)N4C=5C(C(=O)C=C4CCC6=C(F)C(F)=CC=C6)=CC=CN5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
DHBS
DHBS is used in conjunction with 4-aminoantipyrine (4-AAP) and H2O2 for chromogenic quantitation of peroxidase in coupled enzymatic reactions.
-
Methyl?Dihydrojasmon...
Methyl dihydrojasmonate is an ester and a diffusive aroma compound, with the smell vaguely similar to jasmine.
-
Oxindole
Oxindole is an aromatic heterocyclic building block.?2-indolinone derivatives have become lead compounds in the research of kinase inhibitors.Oxindole structure has been used in receptor tyrosine kinases (RTKs) inhibitors such as SU4984 and intedanib, the RTK family represents an important therapeutic target for anti-cancer drug development.
